U.S. Stock Market Midday Update

Calidi Biotherapeutics rose 141.19%. Based on recent important news:

1. On July 8, Calidi Biotherapeutics was featured in a special report by NetworkNewsWire, increasing market attention and driving up the stock price.

2. On July 7, the company announced a collaboration agreement with a large pharmaceutical company, which is expected to significantly enhance its R&D capabilities, leading to a substantial increase in stock price.

3. On July 6, analysts upgraded the company's rating, believing its innovative therapies have huge market potential, causing the stock price to continue to rise.

Stocks with High Trading Volume in the Industry

ProKidney rose 51.34%, with a trading volume of 433 million. Based on recent important news:

1. On July 8, ProKidney announced the Phase II results of its REGEN-007 trial, showing that Rilparencel significantly improved the eGFR slope in chronic kidney disease patients, with no serious adverse events observed, leading to a 51.34% surge in stock price.

2. On July 8, the company stated that the results of REGEN-007 enhanced its confidence in the design of the Phase III PROACT 1 trial and plans to hold a Type B meeting with the FDA to promote the accelerated approval of Rilparencel.

3. On July 9, ProKidney announced that management would participate in important meetings, further boosting market confidence.

Mustang Bio rose 21.42%, with a significant increase in trading volume. Based on recent important news:

1. On July 8, Mustang Bio received FDA orphan drug designation, driving the stock price up 234%. This designation provides tax incentives and market exclusivity for its experimental cancer therapy MB-101.

2. On July 7, MB-101 performed well in Phase I trials, with 50% of patients stabilizing or improving, further enhancing market confidence.

3. On July 8, the global oncology market growth expectations were withdrawn, but it did not negatively impact the stock price